key: cord-0690270-w712vb81
authors: Pahalyants, Vartan; Murphy, William S.; Klebanov, Nikolai; Lu, Chenyue; Theodosakis, Nicholas; Klevens, R. Monina; Estir, Hossein; Lilly, Evelyn; Asgari, Maryam; Semenov, Yevgeniy R.
title: Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: a retrospective matched cohort study from Massachusetts
date: 2021-09-10
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.08.065
sha: fe515ec768542c05b4143aeddccc4250258e1df6
doc_id: 690270
cord_uid: w712vb81

nan

We identified all patients 18 years old and over with at least one prescription for a biologic from July 1, 2019 to Table 1 . TNF inhibitors (adalimumab (28.4%), infliximab (15.6%), and etanercept (11.9%)), CD-20 75 directed antibody (rituximab (15.6%)), and interleukin-4A inhibitor (dupilumab (8.6%)), were the most frequently 76 prescribed biologics. Rheumatoid arthritis (27.5%), psoriasis (27.3%), psoriatic arthritis (16.2%), Crohn's disease 77 (24.9%), and ulcerative colitis (18.9%) were the most common indications for biologics in our study.

Overall, biologics were not associated with COVID-19 (OR 0.88, 95% CI 0.71-1.09, p=0.25), adjusting for 79 demographics, comorbidity burden, and local infection rates ( 

although this difference was not statistically significant (p=0.10). Mortality rates were also similar between the two 83 J o u r n a l P r e -p r o o f

Despite the ongoing vaccination efforts, COVID-19 remains a top health concern. The major finding of our study is 88 that biologics did not increase the risk of positive COVID-19 diagnosis, which are consistent with published 89 literature. 2-4 Additionally, distinct biologics classes are known to cause varying susceptibilities to other viral 90 infections. In our study, TNF inhibitors were associated with lower odds of COVID-19 diagnosis, consistent with 91 reports of this class of biologics being associated with less severe disease among large cohorts of patients. 2,4 92 Furthermore, we did not identify an association between biologics and mortality. Our results must be considered in 

A survey of psoriasis patients on biologics during